PHILADELPHIA — Amyloid beta (Aβ) and tau protein blood biomarkers are highly accurate in identifying Alzheimer’s disease (AD) in patients with cognitive symptoms attending primary and secondary care clinics, new research showed. Accurate early diagnosis of AD is important because two monoclonal antibodies donanemab (Kisunla) and lecanemab (Leqembi) are now approved by the US Food ...
.png)
Copyright © 2024 fu.ci. All Rights Reserved
